DE1939109A1 - 2-methyl-3- [2- (2-diaethylaminoaethoxy) phenyl] quinazolinone- (4) and process for its preparation - Google Patents
2-methyl-3- [2- (2-diaethylaminoaethoxy) phenyl] quinazolinone- (4) and process for its preparationInfo
- Publication number
- DE1939109A1 DE1939109A1 DE19691939109 DE1939109A DE1939109A1 DE 1939109 A1 DE1939109 A1 DE 1939109A1 DE 19691939109 DE19691939109 DE 19691939109 DE 1939109 A DE1939109 A DE 1939109A DE 1939109 A1 DE1939109 A1 DE 1939109A1
- Authority
- DE
- Germany
- Prior art keywords
- methyl
- salts
- quinazolinone
- phenyl7
- phenolate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- -1 (2-hydroxyethoxy) -phenyl7-quinazolinone Chemical compound 0.000 claims description 3
- 239000003513 alkali Substances 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- SZIFAVKTNFCBPC-UHFFFAOYSA-N 2-chloroethanol Chemical compound OCCCl SZIFAVKTNFCBPC-UHFFFAOYSA-N 0.000 claims description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 claims description 2
- 150000004820 halides Chemical class 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 150000007522 mineralic acids Chemical class 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 235000005985 organic acids Nutrition 0.000 claims description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-M phenolate Chemical compound [O-]C1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-M 0.000 claims description 2
- 229940031826 phenolate Drugs 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 125000006012 2-chloroethoxy group Chemical group 0.000 claims 1
- VRZVPALEJCLXPR-UHFFFAOYSA-N ethyl 4-methylbenzenesulfonate Chemical compound CCOS(=O)(=O)C1=CC=C(C)C=C1 VRZVPALEJCLXPR-UHFFFAOYSA-N 0.000 claims 1
- 239000000284 extract Substances 0.000 claims 1
- 239000012442 inert solvent Substances 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical class C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 description 2
- RAGSWDIQBBZLLL-UHFFFAOYSA-N 2-chloroethyl(diethyl)azanium;chloride Chemical compound Cl.CCN(CC)CCCl RAGSWDIQBBZLLL-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 241000282412 Homo Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000003182 bronchodilatating effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 150000002440 hydroxy compounds Chemical class 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
Patentanwälte .· - ". · -Patent attorneys. · - ". · -
ν*-**" ' Br.-fng. von Kreisler Dr.-tag.. SchSnwbld .. . Dr.-fng.Th.M3yer.Dr.ru s Dipl.-Chern.Äteii vor* Kreisler -- Dipl.-Chem Carola Kelier Dr.-lng. Klöpsch - . - Köln, Deichrnannhvu»ν * - ** "'Br.-fng. von Kreisler Dr.-tag .. SchSnwbld ... Dr.-fng.Th.M3yer.Dr.ru s Dipl.-Chern.Äteii before * Kreisler - Dipl.-Chem Carola Kelier Dr.-lng. Klöpsch -. - Cologne, Deichrnannhvu »
2Ία Juli 1969 Fu/ab ,. 2Ί α July 1969 Fu / from,.
i. Köln-Mülheim, Berliner Straße £20-232. i. Cologne-Mülheim, Berli ner Road £ 20-232.
S^iilffiiIhZ^^^^^S ^ iilffiiIhZ ^^^^^
.Von clen zahlreichen in den vergangenen etwa 8O Jahren hergestellten Chinazolinone)-Derivaten haben lediglich eini ge wenige - und diese erst in den letzten 5 Jahren ■* als Hypnotika, Sedative und als Diuretifca Eingang in die Humantherapie gefunden* Einigen anderen wurde in der Patent- und wissenschaftlichen Literatur eine■antikonvulsive, muslcelrelaxierende und bronchodilatätorische Wirksamkeit zugeschrieben, weitere sollen gemäß Literaturhinweisen eine AntSmalaria- und Antihistaminv/irkung aufweisen, Ir^ der» Humanmedizin fanden diese Produkte bisher'aber noch keine ... * ' - ■ . .From clen many made in recent years about 8O quinazolinones) derivatives have only a few eini ge - and found them only in the last 5 years ■ * as hypnotics, sedatives and when Diuretifca input in human therapy * Some other was in the patent - and scientific literature ascribed an anticonvulsive, muscle-relaxing and bronchodilatoric efficacy; according to literature references, others are said to have anti-malarial and antihistamine effects, but in human medicine these products have not yet been found ... * '- ■.
Anwendung, -"·.',.Use, -"·.',.
Bei der pharmakologischen PrUfung einer- gtöSereh Anzahl von Chinazolinondevivaten wf^den üb"erraschenä@rWeise beiIn the pharmacological test there are more than one number of quinazolinone derivatives were surprisingly present
außerordentlich" s'tarke öäemhenanendf Eigenschaften gefundeiij während die anderen oben angefüllten Wirkurigsquaij^Ht-en weitgehend fehl|eno Die Ödemhenimende Wirksamkeit. der obengenannten Verbindung wurde &n verschiedenen ödem- r .modellen der Rattenpfete nachgewiesen«,- Am 7üX'q.r Käoün er-extremely "s'tarke öäemhenanendf properties gefundeiij while the other above-stuffed Wirkurigsquaij ^ Ht-en largely failed | s o Ödemhenimende effectiveness of the above compound was & n different edema r the Rattenpfete .modellen" proven - On 7üX'q r.. Käoün he
■■■■.■ ;: - --:-' :. - ■-■. :■■ fftitog■■■■. ■ ; : - -: - ' : . - ■ - ■. : ■■ fftitog
■ zeugten Pfotenödem erwies sich die Verbindung nach oraler Gabe in einer Dosis im Eereiöh von 10 bis IGO mg/kg als ebenso stark■ ödemheromend wie das wegen seiner starken ■ödemheimnenden Wirkung1 als Yergleichssubstaris herangezogene l,2-Diphenyl-4-n-bütyl-3i5-dioxopyra2olidini Am Eiweiß- und Formal inödem zeigte 2^Methyl-J-^f§-(.2-diäthylaminoUthoxyr phenylpchinazolin-CV, bei oraler Gabe sogar eine eindeutig stärkere Wirkung al S l,2-Dlphenyl-^n-butyl-3>, 5-dioxopy-■razölidln* Diese pharinakologischen Befunde konnten auch in klinischen Versuchen am Menschen bestätigt werden, wobei die Verbindung im Tierversuch und in der Klinik wenig" toxisch unMusgezeichnet verträglich war» ■ produced paw edema, the compound after oral administration in a dose ranging from 10 to IGO mg / kg proved to be just as strongly ■ edema-causing as the 1,2-diphenyl-4-n-butyl used because of its strong ■ edema-suppressing effect 1 as a comparison substance -3 i 5-dioxopyra2olidine i On the protein and formal inedema, 2 ^ methyl-J- ^ f§ - (. 2-diethylaminoUthoxyr phenylpquinazoline-CV, with oral administration even a clearly stronger effect than S 1,2-diphenyl- ^ n-butyl-3>, 5-dioxopy- ■ razölidln * These pharinacological findings could also be confirmed in clinical trials on humans, whereby the compound in animal experiments and in the clinic was not very "toxic and extremely well tolerated"
Gegenstand der Erfindung ist daher ein Verfahren zur"Herstellung von 2-Methyl-3~/2~;2-diäthylaminoäthcxy', -phenyl/-chinazolinon-(;r^ mit der StrukturformelThe invention therefore provides a process for the "production of 2-methyl-3 ~ / 2 ~; 2-diethylaminoethcxy ', -phenyl / -quinazolinone- ( ; r ^ with the structural formula
und dessen Salzen mit physiologisch verträglichen anorganischen und organischen Säuren^ das dadurch gekennzeichnet ist, daß das aus der Literatur bekannte 2-Kethyl-3-/2-hydroxychenyl7-chinazolinon~(4) zunächst mit einem Alkalialkchpiat in Gegenwart eines Lösungsmittels in das Phenolat^libergeführt wird und dieses in an sich bekannter Weise mit einem ß-Diathylaminoäthylhalogenid oder dem äquivalenten ß-Diäthylaminoäthyltosylat bzvio deren Salze mit Mine- ralsäuren umgesetzt wirdo Die besten Ausbeuten werden bei dieser Umsetzung in homogener Phase in Gegenwart von Alkoholen oder anderen polaren Lösungsmitteln erzielt, weniger günstig erfolgt die Reaktion in heterogener Phase., beispiels- : weise durch Kochen in Toluol oder anderen inerten Lösungs-and its salts with physiologically compatible inorganic and organic acids ^ which is characterized in that the 2-Kethyl-3- / 2-hydroxychenyl7-quinazolinone ~ (4) known from the literature first with an alkali alkali in the presence of a solvent in the phenolate ^ is libergeführt and this is reacted ralsäuren in a known manner with a ß-Diathylaminoäthylhalogenid or the equivalent ß-Diäthylaminoäthyltosylat bzvi o their salts with mineral o The best yields are obtained in this reaction in a homogeneous phase in the presence of alcohols or other polar solvents , the reaction takes place less favorably in the heterogeneous phase., for example: by boiling in toluene or other inert solution
■ ■■■.. .: : ;;-: ι■ ■■■ ..:. ; - : ι
mitteln*oder in· Abwesenheit .von Lösungsmitteln*agents * or in the absence of solvents *
Die neue erfindungsgemäße Verbindung ist ferner in an sich bekannter Weise durch Umsetzung von 2-Methyl-J-/^2-hydro::yphenyJ.7-ehinazolinon-(4} mit überschüssigem Kth.ylen.oxyd. oder yithylenchlorhydrin erhältliche In diesem Falle entsteht zunächst das 2-Methy1-5-/2-(2-hydroxy- bzwc -2-chloräthoxy)-phenyl7-chinasolinon-(^}, welches anschließend, im Falle der* Hydroxyverbindung über dessen Halogenid., mit Diethylamin umgesetzt wird«.The new compound according to the invention can also be obtained in a manner known per se by reacting 2-methyl-I - / ^ 2-hydro :: yphenyJ.7-ehinazolinon- (4} with excess ethylene oxide or ethylene chlorohydrin First of all, 2-Methy1-5- / 2- (2-hydroxy- or c -2-chloroethoxy) -phenyl7-quinasolinone - (^}, which is then reacted with diethylamine in the case of the * hydroxy compound via its halide «.
Gegenstand der Erfindung ist weiterhin die -genannte neue Verbindung, gegebenenfalls in Form ihrer Salze mit physiologisch verträglichen Sauren,The invention also relates to the new-mentioned Compound, optionally in the form of their salts with physiological compatible acids,
rii§Jr J-WJ^ZrlBsj'?.-^ rii§Jr J-WJ ^ ZrlBsj '? .- ^
0,2 Mol Natrium werden in 150 ml absolutem Alkohol gelöst., mit 0,1 Mol 2-Kethyl-3-/2-hydroxyphenyl7-chinazolinon-(;t) und 0,1 Mol ß-Diäthylaminoäthylchloridhydrcchlorid versetzt und 4 Stunden am Rückfluß gekochte Nach dem Abdestillieren des Alkohols wird der Bückstand zunächst mit verdünnter Natronlauge und dann mit Äther ausgezogene Die ätherische Lösung wird getrocknet und mit ätherischer Salz säure versetzt. Das ausgefallene 2-Methyl-5-y2-f2-diäthylaminoäthcxy] -phenylZ-ehinazolinon-(4)-dihydrcchlorid zsrsetzt sich unter Gasentwicklung bä 224° bis 2.260C0 Die Ausbeute beträgt 88,4 % der Theorie., bezogen auf das eingesetzte Chinazolinon-(4)ο - ""0.2 mol of sodium are dissolved in 150 ml of absolute alcohol, 0.1 mol of 2-kethyl-3- / 2-hydroxyphenyl7-quinazolinone ( ; t) and 0.1 mol of ß-diethylaminoethyl chloride hydrochloride are added and the mixture is refluxed for 4 hours After the alcohol has been distilled off, the residue is first extracted with dilute sodium hydroxide solution and then with ether. The ethereal solution is dried and ethereal hydrochloric acid is added. The precipitated 2-methyl-5-y2-f2-diäthylaminoäthcxy] -phenylZ-ehinazolinon- zsrsetzt (4) -dihydrcchlorid with gassing bä 224 ° to 0 C 0 2.26 The yield is 88.4% of theory., Based on the Chinazolinone- (4) used ο - ""
Analysenv.'erte: ■ (- ■ -Analysis values: ■ ( - ■ -
0098 107 17610098 107 1761
• ■;.-■--/ '■" . ϊ : -:. a ,-■■ BAD• ■; .- ■ - / '■ ". Ϊ: - :. A, - ■■ BAD
berechnet: C 59,^'; H 6,41: Ol I6,72r Ii 9,SO. gefunden: \- C 59,00; H 6,^5; :Ί l6,72; N 10,01ccalculated: C 59, ^ '; H 6.41: Ol I6.72r Ii 9, SO. found: \ - C 59.00; H 6, ^ 5; : Ί l6.72; N 10.01c
JLrli§J^pyJj:JrZ~A^JLrli§J ^ pyJj: JrZ ~ A ^
92 g Hatriumstücke werden unter Kühlung in 2/5 1 atsolutem
Alkohol'gelost. Die Lösung wird unter Rühren mit 510 g
2-Kethyl-3-/2-hydrQxyphenyl7-chlnazolinon-{4) und dann anteilv;eise,mit
~y\K g Diäthylaminoäthylehloridhydrcchlorid
versetzt. Nach 6-stundigem Kcehen. wird der überE^hifSsige
Alkohol abdestilliertV der Rückstand rnehrfach mit verdünnter Natronlauge und dann init Wasser extrahiert., .anschließend
in Äther aufgenoprnen und· über Natriumsulfat getrcckne-'to Naph
dem Abfiltrieren und Abdampfen des Äthers; wird der Rückstand
in der V.'ärrr.e in, Isoprppariol gelöst und in die LÜsung uriter
Kühlen big zur Beendigung der Fällung Chlorwasserstoff eingeleitet,
ifaeh {|em: Äbfiltrieren uiid frceknen beträgt die
Ausbeute an 2-Methyl-^r-^2-i/2-di^
ehinarolinQn-(^>dihy^rcc;hlQrid f|l g, was einer
sehen Äusgiewte ¥@n BM $ ent^priehtc ·92 g pieces of sodium are dissolved in 2/5 l of absolute alcohol with cooling. The solution is mixed with 510 g of 2-kethyl-3- / 2-hydrqxyphenyl7- c hlnazolinon- {4) and then partially with ~ y \ K g of diethylaminoethyl chloride hydrochloride, while stirring. After 6 hours of cooking. If the excess alcohol is distilled off, the residue is extracted several times with dilute sodium hydroxide solution and then with water, then taken up in ether and dried over sodium sulphate to naph the filtering off and evaporation of the ether; If the residue is dissolved in isopropariol in the vial and introduced into the solution with a little bit of cooling to end the precipitation, hydrogen chloride is then filtered out and then the yield of 2-methyl- ^ r- ^ 2 is -i / 2-di ^
ehinarolinQn - (^> dihy ^ rcc; hlQrid f | lg, what one see Äusgiewte ¥ @ n BM $ ent ^ praises c
.-...:.. BADORiQjNAt.-...: .. BADORiQjNAt
·&- ' ■"".-■ -· & - '■ "" .- ■ -
PP9810/17i1PP9810 / 17i1
Claims (3)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6271868 | 1968-08-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE1939109A1 true DE1939109A1 (en) | 1970-03-05 |
Family
ID=13208386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19691939109 Pending DE1939109A1 (en) | 1968-08-31 | 1969-08-01 | 2-methyl-3- [2- (2-diaethylaminoaethoxy) phenyl] quinazolinone- (4) and process for its preparation |
Country Status (4)
| Country | Link |
|---|---|
| BE (1) | BE737950A (en) |
| DE (1) | DE1939109A1 (en) |
| ES (1) | ES370743A1 (en) |
| FR (1) | FR2016718A1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0054132A1 (en) * | 1980-12-12 | 1982-06-23 | Dr. Karl Thomae GmbH | Pyrimidones, their preparation and medicines containing them |
| US7521455B2 (en) | 2004-02-13 | 2009-04-21 | Banyu Pharmaceutical Co. Ltd. | Fused ring 4-oxopyrimidine derivative |
| US7790731B2 (en) | 2005-02-14 | 2010-09-07 | Banyu Pharmaceutical Co. Ltd. | Crystal form of 2-methyl-3-{4-[3-(1-pyrrolidinyl)propoxy]phenyl}-5-trifluoromethyl-4(3H)-quinazolinone |
-
1969
- 1969-08-01 DE DE19691939109 patent/DE1939109A1/en active Pending
- 1969-08-22 ES ES370743A patent/ES370743A1/en not_active Expired
- 1969-08-25 BE BE737950D patent/BE737950A/xx unknown
- 1969-08-28 FR FR6929508A patent/FR2016718A1/en not_active Withdrawn
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0054132A1 (en) * | 1980-12-12 | 1982-06-23 | Dr. Karl Thomae GmbH | Pyrimidones, their preparation and medicines containing them |
| US7521455B2 (en) | 2004-02-13 | 2009-04-21 | Banyu Pharmaceutical Co. Ltd. | Fused ring 4-oxopyrimidine derivative |
| US8268842B2 (en) | 2004-02-13 | 2012-09-18 | Msd K.K. | Fused ring 4-oxopyrimidine derivative |
| US7790731B2 (en) | 2005-02-14 | 2010-09-07 | Banyu Pharmaceutical Co. Ltd. | Crystal form of 2-methyl-3-{4-[3-(1-pyrrolidinyl)propoxy]phenyl}-5-trifluoromethyl-4(3H)-quinazolinone |
Also Published As
| Publication number | Publication date |
|---|---|
| BE737950A (en) | 1970-02-25 |
| ES370743A1 (en) | 1971-07-01 |
| FR2016718A1 (en) | 1970-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2634288B2 (en) | ||
| DE1770153C3 (en) | Heterocyclic aminoketones, their pharmacologically acceptable acid addition salts and process for their preparation | |
| DE2163911B2 (en) | 2-aminomethyl-phenols, process for the preparation thereof and medicaments containing them | |
| DE1770171C3 (en) | 2,2-Dimethyl-7-alkyl-4- (4-pyridyl) -2H-chromen-5-ols, process for their preparation and medicinal preparations containing these compounds | |
| DD218349A5 (en) | PROCESS FOR PREPARING 2-TERT.-BUTYLAMINO-3-CHLOROPROPIOPHENONE MALEATE | |
| DE1940566C3 (en) | 1- (2-Nitrilophenoxy) -2-hydroxy-3ethylaminopropane, process for its preparation and pharmaceuticals containing it | |
| DE1929950A1 (en) | New trisubstituted 2-arylaminoimidazolines and processes for their preparation | |
| DE2053080C3 (en) | N-substituted imidazoles and their use as drugs | |
| DE1939109A1 (en) | 2-methyl-3- [2- (2-diaethylaminoaethoxy) phenyl] quinazolinone- (4) and process for its preparation | |
| DE2308883C3 (en) | 2-Phenylamino-thienylmethyl-imidazoline- (2), process for the preparation of the same and medicaments containing them | |
| DE2719246A1 (en) | PIPERAZINE DERIVATIVES AND MEDICINAL PRODUCTS CONTAINING THEM | |
| DE2144077C3 (en) | New Hydroxyäthylaminoalkylpiperazines and processes for their preparation | |
| DE1909406A1 (en) | Tricyclic compounds | |
| DE1470002A1 (en) | 5,6-dihydromorphanthridine derivatives | |
| DE1695785C3 (en) | 2-aminomethyl-beitzofurans, processes for their production and preparations containing these compounds | |
| DE3016549A1 (en) | NEW 2-ISOPROPYLAMINO-5-HALOGENOPYRIMIDINE, METHOD FOR THE PRODUCTION THEREOF AND THESE THERAPEUTIC COMPOSITIONS | |
| DE2166662B2 (en) | Dibenzothiazepine derivatives, processes for their preparation and pharmaceuticals containing them | |
| DE1670378A1 (en) | Process for the preparation of a compound from phenylbutazone and ss-diaethylaminoaethylamide of p-chlorophenoxyacetic acid | |
| DE2423897A1 (en) | NEW N- (P-FLUOROBENZOYLPROPYL) -4- PIPERIDYLAMIDES AND THE METHOD FOR THEIR PRODUCTION | |
| DE2053205A1 (en) | Dihydrofurandenvate and process for their preparation | |
| AT325053B (en) | PROCESS FOR THE PREPARATION OF NEW TETRAHYDROPYRIMIDINES, IMIDAZOLINES AND TETRAHYDRO-1,3-DIACEPINES AND THEIR ACID ADDITIONAL SALTS | |
| DE1928027C3 (en) | 7-chloro-6-fluoro-4-chromanonoxime methyl ether, process for its preparation and pharmaceutical preparations containing this compound | |
| DE1792679A1 (en) | Pharmaceutical preparations | |
| DE948153C (en) | Process for the preparation of the higher melting isomer of 2-AEthylcrotonylurea | |
| DE2542154A1 (en) | 6-ARYLOXY-2-OXO-1-AZA-OXA (OR -THIA) -SPIRO SQUARE CLIP ON 4.5 SQUARE BRACKET TO -DECANE, THE PROCESS FOR THEIR MANUFACTURING AND THE MEDICINAL PRODUCTS |